Literature DB >> 1318681

Pentoxifylline modulates activation of human neutrophils by amphotericin B in vitro.

G W Sullivan1, H T Carper, G L Mandell.   

Abstract

The antifungal agent amphotericin B (AmB) alters neutrophil (polymorphonuclear leukocyte [PMN]) function, and this may be the mechanism for some of the adverse effects caused by AmB. AmB is a potent inhibitor of PMN migration, increases PMN adherence and aggregation, and primes PMN for increased oxidative activity in response to a second stimulus. AmB also stimulates mononuclear leukocytes (MNLs) to release inflammatory mediators which augment the effects of AmB on PMN function. In the present study, we observed that the methylxanthine derivative pentoxifylline decreased the effects of AmB on PMN function. AmB (2 micrograms/ml) priming doubled PMN chemiluminescence stimulated by fMet-Leu-Phe. In the presence of MNLs, AmB priming increased fMet-Leu-Phe-stimulated PMN chemiluminescence to 622% of unprimed PMN activity. Pentoxifylline (100 microM) blunted the rise in AmB-augmented PMN chemiluminescence in the presence of MNLs to 282% of unprimed PMN activity, and pentoxifylline metabolites were active at 10 microM. Pentoxifylline (100 microM) also blocked AmB-augmented PMN oxidative activity in whole blood, as measured by nitroblue tetrazolium reduction. In the presence of MNL, AmB (2 micrograms/ml) doubled the expression of the important PMN adherence factor Mac-1. Pentoxifylline (1 mM) decreased AmB-stimulated PMN Mac-1 expression back to unstimulated amounts. In the presence of MNLs, AmB (2 micrograms/ml) decreased PMN nondirected and directed migration to fMet-Leu-Phe to 40 and 38% of control PMN migration, respectively. Pentoxifylline (300 microM) counteracted AmB inhibition of nondirected and directed migration to fMet-Leu-Phe, resulting in migration that was 71 and 87% of control PMN migration, respectively. In contrast, the methylxanthine caffeine (100 muM) increased AmB-enhanced chemiluminescence but did not affect AmB-inhibited PMN migration. Pentoxifylline should be evaluated as adjunctive therapy to lessen the inflammatory damage caused by AmB.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1318681      PMCID: PMC188449          DOI: 10.1128/AAC.36.2.408

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  57 in total

1.  Evidence that oral pentoxifylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine. Results of a pilot study.

Authors:  J A Bianco; J Almgren; D L Kern; B Ballard; K Roark; F Andrews; J Nemunaitis; T Shields; J W Singer
Journal:  Transplantation       Date:  1991-04       Impact factor: 4.939

2.  Pentoxifylline pretreatment decreases the pool of circulating activated neutrophils, in-vivo adhesion to endothelium, and improves survival from hemorrhagic shock.

Authors:  J Barroso-Aranda; G W Schmid-Schönbein
Journal:  Biorheology       Date:  1990       Impact factor: 1.875

3.  Inhibition of neutrophil migration by tumor necrosis factor. Ex vivo and in vivo studies in comparison with in vitro effect.

Authors:  Y Otsuka; K Nagano; K Nagano; K Hori; J Oh-ishi; H Hayashi; N Watanabe; Y Niitsu
Journal:  J Immunol       Date:  1990-10-15       Impact factor: 5.422

4.  Role of myeloperoxidase in intracellular and extracellular chemiluminescence of neutrophils.

Authors:  H L Nurcombe; S W Edwards
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

5.  Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline.

Authors:  R M Strieter; D G Remick; P A Ward; R N Spengler; J P Lynch; J Larrick; S L Kunkel
Journal:  Biochem Biophys Res Commun       Date:  1988-09-30       Impact factor: 3.575

6.  Cyclic nucleotides differentially regulate the synthesis of tumour necrosis factor-alpha and interleukin-1 beta by human mononuclear cells.

Authors:  S Endres; H J Fülle; B Sinha; D Stoll; C A Dinarello; R Gerzer; P C Weber
Journal:  Immunology       Date:  1991-01       Impact factor: 7.397

7.  Effect of an adenosine receptor antagonist on acute amphotericin B nephrotoxicity.

Authors:  C J Kuan; R A Branch; E K Jackson
Journal:  Eur J Pharmacol       Date:  1990-03-27       Impact factor: 4.432

8.  Pentoxifylline modulates meningeal inflammation in experimental bacterial meningitis.

Authors:  X Sáez-Llorens; O Ramilo; M M Mustafa; J Mertsola; C de Alba; E Hansen; G H McCracken
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

9.  Pentoxifylline prevents tumor necrosis factor-induced lung injury.

Authors:  C M Lilly; J S Sandhu; A Ishizaka; H Harada; M Yonemaru; J W Larrick; T X Shi; P T O'Hanley; T A Raffin
Journal:  Am Rev Respir Dis       Date:  1989-06

10.  Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway.

Authors:  J Han; P Thompson; B Beutler
Journal:  J Exp Med       Date:  1990-07-01       Impact factor: 14.307

View more
  9 in total

1.  Effects of pentoxifylline or dexamethasone in combination with amphotericin B in experimental murine cerebral cryptococcosis: evidence of neuroexcitatory pathogenic mechanisms.

Authors:  L Ostrosky-Zeichner; J L Soto-Hernandez; V Angeles-Morales; F Teixeira; C Nava-Ruiz; C Rios; F Solis; J Sotelo
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus.

Authors:  Emmanuel Roilides; Caron A Lyman; Joanna Filioti; Onome Akpogheneta; Tin Sein; Cristina Gil Lamaignere; Ruta Petraitiene; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

3.  Effects of naftifine and terbinafine, two allylamine antifungal drugs, on selected functions of human polymorphonuclear leukocytes.

Authors:  T Vago; G Baldi; D Colombo; M Barbareschi; G Norbiato; F Dallegri; M Bevilacqua
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

4.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

5.  Fluconazole and platelet microbicidal protein inhibit Candida adherence to platelets in vitro.

Authors:  M R Yeaman; P M Sullam; P F Dazin; M A Ghannoum; J E Edwards; A S Bayer
Journal:  Antimicrob Agents Chemother       Date:  1994-07       Impact factor: 5.191

6.  Effect of pentoxifylline in vitro on neutrophil reactive oxygen production and phagocytic ability assessed by flow cytometry.

Authors:  C Wenisch; K Zedtwitz-Liebenstein; B Parschalk; W Graninger
Journal:  Clin Drug Investig       Date:  1997       Impact factor: 2.859

Review 7.  A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity.

Authors:  Zahra Nasiri-Toosi; Simin Dashti-Khavidaki; Hossein Khalili; Mahboob Lessan-Pezeshki
Journal:  Eur J Clin Pharmacol       Date:  2012-11-22       Impact factor: 2.953

8.  Modulation of interactions of Candida albicans and endothelial cells by fluconazole and amphotericin B.

Authors:  M A Ghannoum; S G Filler; A S Ibrahim; Y Fu; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1992-10       Impact factor: 5.191

9.  Pentoxifylline in Prevention of Amphotericin B-induced Nephrotoxicity and Electrolyte Abnormalities.

Authors:  Mahsa Panahi-Shokouh; Azadeh Moghaddas; Shirinsadat Badri; Saeedeh Jabalameli; Mahnaz Momenzadeh; Valiollah Mehrzad; Farzaneh Ashrafi
Journal:  J Res Pharm Pract       Date:  2020-10-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.